Vaccine Trials, Pediatric Clinical and Translational Research Unit

Vaccine Trials Unit Mission:

Addressing health inequities through safe and effective vaccine development/trials with a focus on emerging infections, HIV, and other vaccine preventable conditions.

Pediatric Clinical & Translational Research Unit Mission:

Leading innovative clinical and translational research to improve the health and well-being of all children, with emphasis on minority and medically underserved children in Georgia, US, and worldwide.

MSM COVID 19 Vaccine Trial Interest Survey

Please fill out the survey if you are interested and be a part of the changing face of research in this diverse community.

Take the Survey

MSM COVID 19 Vaccine Trial Interest Survey

Please fill out the survey if you are interested and be a part of the changing face of research in this diverse community.

Take the Survey

TWINKLE

A Phase 3a, observer blind, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational combined measles, mumps, rubella, and varicella vaccine compared with intramuscular administration of ProQuad when administered as a second dose to healthy children aged 15 months to 6 years of age.

Learn More

PSK00026

A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2-arm study to investigate the safety and immunogenicity of a single dose of a 21-valent pneumococcal conjugate vaccine in children and adolescents ages 2-17 with sickle cell disease. The 21-valent pneumococcal conjugate vaccine (PCV21) is an investigational vaccine designed to offer broad protection against pneumococcal disease. It includes 21 serotypes—20 shared with the 20-valent PCV Prevnar 20TMa (20vPCV) plus one additional serotype (9N). These serotypes are conjugated to two carrier proteins: tetanus toxoid (TTxd) or a non-toxic mutant of diphtheria toxin (CRM197). Currently enrolling at multiple U.S. sites and in the DR

Learn More